Abbott Labs has reached an impasse with the Brazilian government in the negotiations over the price of new anti-AIDS drug, Kaletra. The Brazilian government is threatening compulsory licensing if Abbott drastically reduces the price of Kaletra. "Hide
by Rohit Deshpande, Ricardo de-Reisen Pinho Source: Harvard Business School 4 pages. Publication Date: February 23, 2006. Prod. #: 506062-PDF-ENG
